Treatment outcomes with fluoroquinolone-containing regimens for isoniazid-resistant pulmonary tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 1, 2016, Pages 471-477

  Lee, Hyun ^a   Jeong, Byeong Ho ^a   Park, Hye Yun ^a   Jeon, Kyeongman ^a   Huh, Hee Jae ^a   Lee, Nam Yong ^a   Koh, Won Jung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ANTIBIOTIC RESISTANCE; COMBINATION DRUG THERAPY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RECURRENT DISEASE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ADULT; AGED; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HUMANS; ISONIAZID; LEVOFLOXACIN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84957877762     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01377-15     Document Type: Article

References (28)

1. World Health Organization. 2014. Global tuberculosis report 2014. WHO, Geneva, Switzerland. http://www.who.int/tb/publications/global-report/en/.
2. Mitchison DA, Nunn AJ. 1986. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 133:423-430.
3. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baez J, Kochi A, Dye C, Raviglione MC. 2000. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283:2537-2545. http://dx.doi.org/10.1001/jama.283.19.2537.
4. Seung KJ, Gelmanova IE, Peremitin GG, Golubchikova VT, Pavlova VE, Sirotkina OB, Yanova GV, Strelis AK. 2004. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis 39:1321-1328. http://dx.doi.org/10.1086/425005.
5. Lew W, Pai M, Oxlade O, Martin D, Menzies D. 2008. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 149:123-134. http://dx.doi.org/10.7326/0003-4819-149-2-200807150-00008.
6. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, Vernon A, Lienhardt C. 2009. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 6:e1000150. http://dx.doi.org/10.1371/journal.pmed.1000150.
7. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 167:603-662. http://dx.doi.org/10.1164/rccm.167.4.603.
8. National Institute for Health and Care Excellence. 2011. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. NICE, London, United Kingdom. http://www.nice.org.uk/guidance/CG117.
9. World Health Organization. 2009. Treatment of tuberculosis: guidelines for national programmes. WHO, Geneva, Switzerland. http://www.who.int/tb/publications/tb-treatmentguidelines/en/.
10. Escalante P, Graviss EA, Griffith DE, Musser JM, Awe RJ. 2001. Treatment of isoniazid-resistant tuberculosis in southeastern Texas. Chest 119:1730-1736. http://dx.doi.org/10.1378/chest.119.6.1730.
11. Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Lim SY, Lim SY, Koh WJ. 2008. Treatment of isoniazid-resistant pulmonary tuberculosis. BMC Infect Dis 8:6. http://dx.doi.org/10.1186/1471-2334-8-6.
12. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM, Osmond D, Hopewell PC, Nahid P. 2009. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis 48:179-185. http://dx.doi.org/10.1086/595689.
13. Bang D, Andersen PH, Andersen AB, Thomsen VO. 2010. Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome. J Infect 60:452-457. http://dx.doi.org/10.1016/j.jinf.2010.03.017.
14. Fox L, Kramer MR, Haim I, Priess R, Metvachuk A, Shitrit D. 2011. Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis 30:863-867. http://dx.doi.org/10.1007/s10096-011-1167-4.
15. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. 2011. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis 53:369-372. http://dx.doi.org/10.1093/cid/cir406.
16. Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. 2012. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. Int J Tuberc Lung Dis 16:812-816. http://dx.doi.org/10.5588/ijtld.11.0637.
17. Wang TY, Lin SM, Shie SS, Chou PC, Huang CD, Chung FT, Kuo CH, Chang PJ, Kuo HP. 2014. Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis. PLoS One 9:e86316. http://dx.doi.org/10.1371/journal.pone.0086316.
18. Reves R, Heilig CM, Tapy JM, Bozeman L, Kyle RP, Hamilton CD, Bock N, Narita M, Wing D, Hershfield E, Goldberg SV. 2014. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. Int J Tuberc Lung Dis 18:571-580. http://dx.doi.org/10.5588/ijtld.13.0304.
19. Munang ML, Kariuki M, Dedicoat M. 2015. Isoniazid-resistant tuberculosis in Birmingham, United Kingdom, 1999-2010. QJM 108:19-25. http://dx.doi.org/10.1093/qjmed/hcu139.
20. Chien JY, Chen YT, Wu SG, Lee JJ, Wang JY, Yu CJ. 2015. Treatment outcome of patients with isoniazid mono-resistant tuberculosis. Clin Microbiol Infect 21:59-68. http://dx.doi.org/10.1016/j.cmi.2014.08.008.
21. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, Lee JK, Kim SJ. 2007. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 11:571-576.
22. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, Choi YS, Kim K, Kim J, Shim YM, Koh WJ. 2008. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 47:496-502. http://dx.doi.org/10.1086/590005.
23. Koh WJ, Lee SH, Kang YA, Lee CH, Choi JC, Lee JH, Jang SH, Yoo KH, Jung KH, Kim KU, Choi SB, Ryu YJ, Chan Kim K, Um S, Kwon YS, Kim YH, Choi WI, Jeon K, Hwang YI, Kim SJ, Lee YS, Heo EY, Lee J, Ki YW, Shim TS, Yim JJ. 2013. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med 188:858-864. http://dx.doi.org/10.1164/rccm.201303-0604OC.
24. Fox W, Ellard GA, Mitchison DA. 1999. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3:S231-S279.
25. Nolan CM, Goldberg SV. 2002. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Int J Tuberc Lung Dis 6:952-958.
26. World Health Organization. 2014. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO, Geneva, Switzerland. www.who.int/tb/publications/pmdt-companionhandbook/en/.
27. Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183. http://dx.doi.org/10.2165/00003495-200262150-00001.
28. Kim SJ. 2005. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 25:564-569. http://dx.doi.org/10.1183/09031936.05.00111304.